Roche Venture Fund and Enterprise Ireland have committed an additional 3.3 million, or $4.5 million, to the series B financing announced by Opsona Therapeutics this February. This brings the total series B financing to 21.3 million, or $29 million. Previous investors include Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital, and Seroba-Kernel.
The financing supports the expansion of Opsona's clinical development pipeline, targeting inflammatory and autoimmune disease such as rheumatoid arthritis and lupus.
"We are delighted by the caliber of investors who have supported our Series B financing," says Mark Heffernan, CEO of Opsona Therapeutics. "The investment by Roche Venture Fund is a further endorsement of Opsona's approach to targeting the innate immune system, and the continued support of Enterprise Ireland demonstrates their commitment to investment in high-potential companies."